Those 2 cents can see big profits, says Oppenheimer
Lines drawn in the sand in Washington hold another incentive as a hostage, but what does that mean for Wall Street? Despite the deadlock on Capitol Hill, the S&P 500 rose 9.5 percent from its recent low on Sept. 23, based on strong economic data. Against this background, investors and economists are beginning to wonder whether the latest economic data better than expected suggests that earlier stimulus packages will be sufficient to support the economy as we move into the world after COVID. Oppenheimer̵
7;s chief investment strategist John Stolzfuss points out that “with all the increases in uncertainty that have occurred since early September,” markets in the United States and international markets are “recovering and even coming together to the horror of bears, skeptics, perennial nerves and even some DC Beltway residents. ” Moreover, as stocks have risen, so has the 10-year bond yield. So what did the “magic” do in the markets? Stoltzfus highlights a “mixed bag of factors,” including a third-quarter earnings season starting this week with big banks, economic data that opposes the recent economic slowdown, interest rates that remain close to historic lows, and ” the feeling that the outcome of the election is unlikely to lead to a prolonged period of uncertainty. Stoltzfus also believes that markets view COVID-19 as more of a “detour from the broader forces that work to drive stocks in the US stock market.” In view of this, Oppenheimer analysts have stopped at this, which they say are exciting opportunities.These are names that will not break the bank and boast colossal growth prospects for the twelve months ahead, namely pennies.These tickers, costing less than $ 5 apiece, are tough Using some TipRank database, we got all the details to understand why they are so compelling, even with the associated risk.Outlook Therapeutics (OTLK) First we have Outlook Therapeutics, which focuses on developing and commercializing of Lytenava, a complex monoclonal antibody, for various ophthalmic indications.After a recent report, Oppenheimer believes the share price of $ 0.77 is an attractive entry. one point. OTLK published first-class data from Lytenava’s NORSE-1 study against Genentech and Luche’s Roche in age-related wet macular degeneration (AMD), a condition that can cause vision loss. In the group receiving OTLK therapy, 2 of 25 (8%) patients reached the primary endpoint (gain of at least 15 letters with the best visual acuity assessment), and the group receiving Lucentis had 5 of 23 (22%) achieved by weighing this result for Oppenheimer, analyst Leland Gershell points out that although this was a key study, it was indeed a clinical study to generate data on use. In addition, while more patients with Lucentis reached the primary endpoint, the analyst mentioned that the comparison group included about twice as many patients who had not received treatment and / or had poorer baseline vision, which favors Lucentis. The company said more than 15 letter improvements in month 11 were “ambiguous among untreated patients” and improved better for Lytenava among those with visual acuity at baseline of less than 67 letters, up from 44%. at Lucentis.Gershell added: “We believe the results support Lytenava’s prospects in the current US NORSE-2 trial in wet AMD, which is well-powered to show superiority in efficiency over Lucentis. “Together with the sufficient sample size for statistical feeding, NORSE-2 will stratify according to certain baseline characteristics, exclude patients with better vision than 20/50, and include only patients who were not treated during treatment. As Lytenava is positioned to play a significant role in the multibillion-dollar market for retinal diseases, a licensing agreement or partnership is not ruled out, according to Herschel, for which it recommends investors to withdraw shares before NORSE-2 reporting. above, Gershell evaluates OTLK with a better result (ie purchase), together with a price price of $ 8. Investors can gain a profit of 947% if this goal is met in the next twelve months. watch the Gershell record, click here) Turning now to the rest of the street, 3 purchases and no arrests or sales have been posted in the last three months, so OLTK has a strong consensus rating. with the average price price reaching $ 6.33, the potential for increase reaches 729%. (See OLTK stock analysis for TipRanks) Organogenesis Holdings (ORGO) As one of the best companies in regenerative medicine, Organogenesis Holdings focuses on empowering the healing forces by developing products for the wound care, surgical and sports medicine market. . With a share price of $ 3.85, Oppenheimer says now is the time to pull the trigger. Company analyst Stephen Lichtman is considered a fan. Although sales fell 29% year-on-year in April, trends began to improve in May as healthcare facilities began to reopen. By June, more than 90% of ORGO’s client accounts had been opened and all were accepting new patients. As a result, sales for the second quarter of 2020 of $ 69 million blew expectations. In addition, despite the opposite winds associated with COVID, management has restored its original sales targets for 2020 from $ 273 million to $ 277 million, which will reflect 5-6% profit for the year. Going forward, Lichtman cites Affinity, the company’s fresh amniotic membrane. care and surgery as a key moment of strength. After switching to a new contract manufacturer and subsequent re-launch in 1H20, the analyzer sees strong winds, and on top of that the ramp of NuShield, a dehydrated placental allograft, and NovaChor, the first fresh chorionic membrane, can lead significantly upwards. Lichtman added: “Management has also emphasized the benefits of the breadth of its products, as customers are increasingly seeking to reduce the number of suppliers they use.” ORGO believes that its product mix can lead to a margin expansion. “ORGO’s amniotic portfolio contributes significantly as it is a high-margin product and a key component for the company’s growth. The consolidation of several facilities is also expected to improve the margin of ~ 300 basis points, “said Leachman. It should be noted that since the recovery of the recovery in Q4 2018, ORGO has taken steps to manage PuraPly (its medical device designed to manage acute and chronic wounds in a wide range of types of wounds) outside the transition. These efforts include increasing the penetration of doctor’s offices, improving clinical data, adding products and extensions to the PuraPly lines, and launching smaller sizes at a price below the package. Calling these efforts “short-term compensations”, Lichtman believes that they represent “potential positive aspects of expectations”. Everything ORGO did about it convinced Lichtman to value the shares more efficiently (ie buy) along with a price price of $ 9. This figure suggests a 134% potential for increase compared to current levels. (To watch Lichtman’s recording, click here) In general, other analysts echo Lichtman’s mood. 3 Purchases and no retentions or sales are added to the strong purchase rating. With an average price of $ 8.67, the potential for growth is 126%. (See an analysis of ORGO shares for TipRanks.) To find good penny ideas that are traded at attractive rates, visit TipRanks’ Best Buy Shares, a newly created tool that brings together all insights into TipRanks ownership. Disclaimer: The views expressed in this article are those of the analysts submitted. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.